The CVS-Tempus partnership aims to streamline the cancer care process for patients from the point of prescribing onwards and connect patients with local trials.
Invitae will provide genetic testing for 109 genes associated with the conditions, while BioMarin will provide financial support for the program.
The platform matches a patient's medical history and other data with national guidelines to recommended medically actionable genetic tests.
PWNHealth will enable Stratify to offer its Prompt Personal Genetic Score prostate cancer genetic risk test directly to consumers with medical oversight.
The firm will use funds from the round, led by the Midlands Engine Investment Fund, to develop its optical point-of-care diagnostic testing platform.
The genetic testing firm is offering approximately 2.3 million shares at $11.25 per share and plans to use the funds for general corporate purposes.
Northern California healthcare system NorthBay Healthcare will evaluate the platform's ability to improve the routine use of genetic testing.
Invitae is providing the testing services as part of the 12-month pilot, while patients will have the option to share their results with researchers though LunaDNA.
The educational grant will support UpToDate's development of technology to help medical professionals advise their patients on health implications of genetic tests.
The defendants, which include people associated with genetic testing labs, allegedly billed Medicare over $2.1 billion for unnecessary tests.